Back to Home
Featured

Exploring Emerging Targeted Therapies in Relapsed Small Cell Lung Cancer

June 20, 2024 | 11:45 AM CT

Countdown to Event

00

Days

00

Hours

00

Mins

00

Secs

Stream link: https://event.arraylive.com/app/login/1681d17b-0ad7-4363-8800-906e986b426b

A satellite symposium in conjunction with Oncology Pharmacists Connect: Summer 2024.

This activity will be broadcasted live from Austin, TX. To attend the full conference, please register here.

Program Description

Small cell lung cancer (SCLC) is typically more aggressive and more difficult to treat than non—small cell lung cancer due to rapid tumor growth and quick development of resistance. This session focuses on therapeutic updates in SCLC, emphasizing advancements in treatment strategies and the management of toxicities. Expert faculty will review the epidemiology of SCLC, risk factors, and challenges with limited frontline treatments. The emergence of second-line therapies, combination therapies, and potential novel treatment regimens will be discussed. Oncology pharmacists are central figures in the health care team as they participate in therapy discussions and assist in managing treatment-related toxicities. Included patient case scenarios present considerations for applying these strategies, evaluating new therapeutic approaches, and mitigating adverse effects of therapy.


Target audience: Oncology pharmacists

Type of activity: Application
Release date: June 20, 2024
Expiration date: August 20, 2024

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Compare the pharmacology and toxicology of novel and emerging treatments for relapsed extensive-stage small cell lung cancer (ES-SCLC)
  • Analyze the latest clinical evidence for second-line and subsequent systemic therapies in ES-SCLC
  • Determine interventions and therapeutic monitoring strategies for treatment-related toxicities associated with systemic therapies in ES-SCLC